SANOFI-AVENTIS has launched
a hostile bid for Genzyme, after
management at the target
company refused to negotiate.
The US$69 per share offer is at
the same price already rebuffed by
Genzyme a month ago, but is now
being offered directly to Genzyme
shareholders.
Sanofi-aventis ceo Chris
Viehbacher said “we believe the
offer will be successful ultimately.
“Sanofi-aventis has a history of
being a patient, disciplined buyer.”The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 10
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.